Currently worth a few million dollars, the emerging organs-on-chips market has the potential to become a multi-billion dollar market.
Organs-on-chips: the promise of solving one of the pharmaceutical industry’s major hurdles
Bringing a new drug to market is one of the longest and most costly paths any industry has to walk. Companies start with several thousands of compounds that may have positive effects against a disease or a human condition. More than twelve years and several billion dollars later, if they’re lucky they managed to get one of these compounds onto the market. All the others failed at one stage or another during the drug development process – and the later the failure, the more expensive it is. Current methods – cell culture in petri dishes and animal testing among others – are not predictive enough. Around 90% of drugs that have been validated on these models then fail during clinical trials because of toxicity or lack of efficacy. The pharmaceutical industry therefore needs more predictive tools to make drug candidates fail earlier and cheaper. Other industries where toxicity testing is a major concern, such as cosmetics, agro-food and consumer goods, also need such solutions, in particular because animal testing is now banned for these industries in certain geographical areas. Several options have been envisioned, the most promising of which is certainly organs-on-chips. These combinations of micro-technology and biology reconstitute the physiological and mechanical functions of human organs under the form of micro-engineered devices lined with living cells. Precisely controlled fluid flows combined with mechanical cues and tissue-tissue interfaces enable dynamic models, much more relevant than conventional static cell cultures. As a sign of confidence in this technology, significant funding has been allocated to organs-on-chips developers: DARPA and the NIH respectively awarded $140M and $76M over 5-year periods to support developments. In parallel, technology developers have raised more than $80M since 2012 with investors. In Yole Développement’s report, all the key elements to understand the organs-on-chips landscape are detailed.
For more information, please visit our website: https://www.i-micronews.com/reports.html
An organ-on-a-chip (OOC) is a multi-channel 3-D microfluidic cell culture chip that simulates the activities, mechanics and physiological response of entire organs and organ systems, a type of artificial organ. It constitutes the subject matter of significant biomedical engineering research, more precisely in bio-MEMS. The convergence of labs-on-chips (LOCs) and cell biology has permitted the study of human physiology in an organ-specific context, introducing a novel model of in vitro multicellular human organisms. One day, they will perhaps abolish the need for animals in drug development and toxin testing.
Organs on a chip are multichannel 3D microfluidic cell culture chips that simulate the activities, mechanisms, and physiological responses of entire human organs. These chips recreate the smallest functional units of organs in a microenvironment mimicking the human body. Organs on chip can replace animal models in pharmaceutical research by allowing studies of drug interactions, pathogen responses, and toxicity testing in human organ systems. This technology is expected to help accelerate drug development and discovery.
This document discusses methods for clinical testing, specifically 3D cell culture and organ-on-chip technologies. It notes that animal testing is time-consuming, costly, and often does not predict human outcomes. Organ-on-chip technologies use microfabrication and microfluidics to create microenvironments that better simulate human physiology and organs. This allows for testing of drugs and toxins using human cells in a way that may replace animal models. Examples discussed include a lung-on-a-chip to study pulmonary edema and a proposed "body on a chip" with 3D printed miniature organs to improve drug development and reduce costs.
This document discusses organ-on-a-chip technology. It describes organ-on-a-chip as a multi-channel 3D microfluidic cell culture chip that simulates the activities, mechanics, and physiological responses of entire organs and organ systems. Each organ chip is about the size of an AA battery and mimics cell responses more accurately than traditional in vitro cultures. The chips allow researchers to observe organ functionality, behavior, and responses at the cellular and molecular levels. Organ-on-a-chip aims to recreate the smallest functional units of organs in microenvironments that closely mimic the human body.
Organ-on-a-chip technology provides a novel in vitro platform with a possibility of reproducing physiological functions of in vivo tissue, more accurately than conventional cell-based model systems. Many newly arising diseases result from complex interaction between multiple organs.
An organ-on-a-chip (OOC) is a multi-channel 3-D microfluidic cell culture chip that simulates the activities, mechanics and physiological response of entire organs and organ systems, a type of artificial organ
Microfluidics and organ on a chip technology is an interdisciplinary field of medical and engineering. It will replace the current methods of testing efficacy of drug viz. cells in dishes test and animal testing.
Organs-on-a-chip are microfluidic cell culture chips that mimic human organs. They are about the size of an AA battery and contain channels lined with living human cells on a transparent chip. This allows scientists to observe cell behavior and responses under physiological conditions, including fluid flow and mechanical forces. Organs-on-chips can help address issues with drug development by providing more accurate and predictive models of how drugs will interact with human organs before clinical trials. They have the potential to reduce drug development costs and timelines compared to current animal models and cell cultures.
An organ-on-a-chip (OOC) is a multi-channel 3-D microfluidic cell culture chip that simulates the activities, mechanics and physiological response of entire organs and organ systems, a type of artificial organ. It constitutes the subject matter of significant biomedical engineering research, more precisely in bio-MEMS. The convergence of labs-on-chips (LOCs) and cell biology has permitted the study of human physiology in an organ-specific context, introducing a novel model of in vitro multicellular human organisms. One day, they will perhaps abolish the need for animals in drug development and toxin testing.
Organs on a chip are multichannel 3D microfluidic cell culture chips that simulate the activities, mechanisms, and physiological responses of entire human organs. These chips recreate the smallest functional units of organs in a microenvironment mimicking the human body. Organs on chip can replace animal models in pharmaceutical research by allowing studies of drug interactions, pathogen responses, and toxicity testing in human organ systems. This technology is expected to help accelerate drug development and discovery.
This document discusses methods for clinical testing, specifically 3D cell culture and organ-on-chip technologies. It notes that animal testing is time-consuming, costly, and often does not predict human outcomes. Organ-on-chip technologies use microfabrication and microfluidics to create microenvironments that better simulate human physiology and organs. This allows for testing of drugs and toxins using human cells in a way that may replace animal models. Examples discussed include a lung-on-a-chip to study pulmonary edema and a proposed "body on a chip" with 3D printed miniature organs to improve drug development and reduce costs.
This document discusses organ-on-a-chip technology. It describes organ-on-a-chip as a multi-channel 3D microfluidic cell culture chip that simulates the activities, mechanics, and physiological responses of entire organs and organ systems. Each organ chip is about the size of an AA battery and mimics cell responses more accurately than traditional in vitro cultures. The chips allow researchers to observe organ functionality, behavior, and responses at the cellular and molecular levels. Organ-on-a-chip aims to recreate the smallest functional units of organs in microenvironments that closely mimic the human body.
Organ-on-a-chip technology provides a novel in vitro platform with a possibility of reproducing physiological functions of in vivo tissue, more accurately than conventional cell-based model systems. Many newly arising diseases result from complex interaction between multiple organs.
An organ-on-a-chip (OOC) is a multi-channel 3-D microfluidic cell culture chip that simulates the activities, mechanics and physiological response of entire organs and organ systems, a type of artificial organ
Microfluidics and organ on a chip technology is an interdisciplinary field of medical and engineering. It will replace the current methods of testing efficacy of drug viz. cells in dishes test and animal testing.
Organs-on-a-chip are microfluidic cell culture chips that mimic human organs. They are about the size of an AA battery and contain channels lined with living human cells on a transparent chip. This allows scientists to observe cell behavior and responses under physiological conditions, including fluid flow and mechanical forces. Organs-on-chips can help address issues with drug development by providing more accurate and predictive models of how drugs will interact with human organs before clinical trials. They have the potential to reduce drug development costs and timelines compared to current animal models and cell cultures.
What are Organs-on-chips?
The Organs-on-Chips are crystal clear, flexible polymers about the size of a computer memory stick that contain hollow channels fabricated using computer microchip manufacturing techniques.
These channels are lined by living cells and tissues that mimic organ-level physiology.
Organs-On-Chips Market and Technology Landscape 2019 report by Yole Développe...Yole Developpement
This report provides an analysis of the organ-on-chip market and technology from 2019-2024. It includes market forecasts for organ-on-chip device sales and services through 2024. It also examines the organ-on-chip ecosystem and supply chain, as well as technology trends like the types of organ models, devices, materials, and cell sources used. The report aims to help pharmaceutical, biotech, and other companies understand organ-on-chip technologies and how they can be used for drug development, disease modeling, and toxicity testing applications.
The Promise of Next-Generation Animal Management SystemsCognizant
Pharmaceuticals, biotech and device companies are searching for more robust next-gen animal management systems to help them enhance efficiencies, reduce costs and adhere to regulatory principles for humane animal care. This is an overview of existing systems, and the benefits, challenges, trends and technologies driving them.
Point-of-Need Testing: Application of Microfluidic Technologies - 2018 Report...Yole Developpement
Decentralized testing is now widespread, thanks to the endless possibilities enabled by microfluidic technologies.
More information on that report at https://www.i-micronews.com/report/product/point-of-need-testing-application-of-microfluidic-technologies.html
Microfluidics market outlook Lab On Chip Europe Presentation by Benjamin Rous...Yole Developpement
The document discusses the microfluidics market and industry trends. It provides the following key points:
1) The microfluidics market reached $2.2 billion in 2014 and is growing at a 28% CAGR, though the market remains highly fragmented across applications.
2) The microfluidics industry is consolidating as some companies go public, major diagnostic firms make acquisitions, and the supply chain matures.
3) The technology has moved from the "peak of inflated expectations" to the "slope of enlightenment" on the Gartner Hype Cycle as value is recognized and manufacturing improves.
Status of the Microfluidics Industry 2019 report by Yole Développement Yole Developpement
Diversification of microfluidic technologies has led to burgeoning new applications and market growth, driving players’ interest and M&A.
More information on https://www.i-micronews.com/products/status-of-the-microfluidics-industry-2019/
This document summarizes a presentation on organoids in immunological research. It begins with an overview of organoids, describing them as 3D cultures derived from adult stem cells that recapitulate tissue architecture. Section 1 discusses the tissue-like structure of organoids and self-organization principles. Section 2 explains how organoids can be used to study interactions between epithelial cells and immune cells, and how this improves understanding of homeostasis, infection responses, and fetal development. Section 3 discusses applications of organoid technology in personalized medicine and future directions.
The document discusses organoids, which are 3D clusters of cells grown in vitro to mimic organ structures. It describes the 5 basic steps to make an organoid: 1) obtain a tissue sample, 2) dissociate it into single cells, 3) isolate stem cells using a cell sorter, 4) add the stem cells to a gel-like substance called Matrigel, and 5) allow the cells to grow over 1-90 days. Various types of organoids are listed, and potential uses discussed, including testing medical/chemical agents, aiding drug development by reducing animal testing, and regenerative medicine by growing replacement organs.
Multiorgan Microdevices for ADME Evaluatio and Drug Design:-
Multi-organ micro-devices are microfluidic devices that gives the information of human metabolism by connecting the fluidic streams from several on-chip in vitro tissue cultures with each other in a physiologically relevant manner. Multi-organ micro-devices can predict tissue-tissue interactions that occur as a result of metabolite travel from one tissue to other tissues in vitro. These systems are capable of simulating human metabolism, including the conversion of a pro-drug to its effective metabolite as well as its subsequent active metabolite and toxic side effects. Since tissue-tissue interactions in the human body can play a significant role in determining the success of new pharmaceuticals, the development and use of multi-organ micro-devices present an opportunity to improve the drug development process. The devices have the potential to predict potential toxic side effects with higher accuracy before a drug enters the expensive and time consuming phase of clinical trials. Further, when operated with human biopsy samples, the devices could be a way for the development of individualized medicine. Since single organ devices are testing platforms for tissues that can later be combined with other tissues within multi-organ devices, we will also mention single organ devices where appropriate in the discussion those seems large area of interest in current research for individualized medicine and drug resistance study.
This document discusses the role of nanotechnology in pharmacology and drug delivery. It begins with definitions of nanotechnology and nanobiotechnology, then describes applications of nanobiotechnology including nanopharmacology. The key roles of nanotechnology in drug discovery and development, and drug delivery systems are summarized. Specific nanocarrier platforms like liposomes, polymeric nanoparticles, dendrimers, and nanocrystals are discussed in terms of their advantages and challenges for drug delivery. The role of nanodrugs in personalized medicine is also mentioned.
Point-of-Need Testing: Application of Microfluidic Technologies - 2016 Report...Yole Developpement
Decentralized testing for both human and non-human in-vitro diagnostics is increasingly taking advantage of innovative microfluidic technologies
PLENTY OF APPLICATIONS HAVE STARTED TO BENEFIT FROM MICROFLUIDICS FOR DECENTRALIZED TESTING, BUT HAVE NOT REALIZED THEIR FULL POTENTIAL – YET
Point-of-Care (PoC) testing is not a new concept - the first applications arose in the 1990s. Since then, microfluidic technologies have been increasingly used to solve technical problems and bring economic benefits to the healthcare industry. In the past few years, other applications have benefited from recent technological improvements: veterinary testing, environmental testing, agro-food and industrial testing are also part of the scope of the report. Decentralized testing brings significant operational benefits to various players across these applications.
Microfluidics is part of the diagnostics revolution, with an explosion in the number of products on the market. However, with many applications but few solutions existing today, these markets have not yet reached their full potential.
In the report, Yole Développement (Yole)’s analysts explain why the human healthcare market still looks much more attractive to technology developers. However, in the near future the greatest opportunities will be in all the other markets. The report also explores which barriers still need to be taken down for decentralized, or “point-of-need” (PoN), testing to flourish.
Microfluidics-based point-of-need testing will grow from a $2.6B market in 2015 to $10.3B in 2021, which is a 26% compound annual growth rate (CAGR). This value represents more than 500 million tests in 2021, but only 61 million will be outside human diagnostics. In the report, Yole’s analysts detail the evolution of each application in terms of microfluidic technology’s use.
07b. Nanotechnologies for diagnostics and nanomedicine
Lab on a chip: Miniaturization, Soft lithographies, microfluidics (Navier-Stokes equations, laminar flow in microchannels, main microfluidic components), Selected applications to chemical microreactors, separation systems and Lab On a Chip.
Detailed idea on nanotechnology, nanomedicine, types, uses, pharmacotherapy, and future prospects of the nanotechnology. Drug delivery systems, Pharmacokinetics and pharmacodynamics of the nanoparticles are dealt in detail
This document provides an overview of microfluidics presented by Rajan Arora. It defines microfluidics as manipulating small amounts of fluids using channels 10-100 micrometers in size. Typical microfluidic systems are described including a DNA separation system and lab-on-a-chip for diagnosing heart attacks. The origins and history of microfluidics are discussed from Richard Feynman's 1959 talk to developments in the 1990s. Key components, physics principles, and flow mechanisms of microfluidic systems are explained. Various applications are highlighted such as lab-on-a-chip, low-cost paper and plastic-based microfluidics, and emerging uses in textiles, optofluidics and acou
Cell culture is the process of growing cells outside their natural environment. Key events in the history of cell culture include Wilhelm Roux maintaining chicken tissue in saline in 1885, and Harrison establishing the first cell culture in 1907. Traditionally, cells were cultured in 2D monolayers, but 3D cell culture has emerged as a way to better mimic the in vivo microenvironment. 3D cultures can be scaffold-based, using matrices like collagen, or scaffold-free, allowing cell-cell interactions. Technologies like microfluidics and bio-MEMS now aid 3D cell culture research. Careful planning is required to properly design and safely operate a cell culture laboratory.
Lab-on-a-chip technology integrates laboratory functions onto a single chip only millimeters in size through microfluidics and electronic components. Lab-on-chip devices use materials like glass, silicon, polymers and metals in fabrication processes like deposition, etching, and bonding. They contain microchannels for fluid flow and can integrate nanosensors, allowing portable chemical analysis and detection of small molecules. Applications include point-of-care diagnostics, pollution monitoring, and medical testing. Future advancements will rely on microfluidics and molecular biology with nanotechnology playing a key role.
The document discusses how artificial intelligence can help address challenges posed by infectious diseases. It describes how AI uses past disease data to predict outbreaks, and how algorithms created from behavioral and epidemiological data can help target prevention efforts. The document also outlines several successes of AI in predicting disease outbreaks like dengue fever in advance. Overall, the document advocates that AI has great potential to help monitor infectious diseases and facilitate more proactive public health responses if its tools are developed and applied effectively.
National guidelines for stem cell research-2017akshaya tomar
The document provides guidelines for stem cell research in India. It classifies stem cell research into permissible, restrictive, and prohibited areas based on ethical and safety concerns. It outlines responsibilities of researchers and institutions in obtaining approvals and ensuring informed consent, safety, and oversight for stem cell derivation, manipulation, and clinical applications. The aim is to promote rigorous scientific research while preventing premature commercialization of unproven stem cell therapies.
Microfluidic Applications 2015 Report by Yole DeveloppementYole Developpement
This document provides a summary and analysis of the microfluidic applications market from 2013 to 2020. It includes:
- An overview of key market segments and the status of the microfluidic market since 2013.
- Market data and forecasts for the microfluidic devices market, which is projected to reach $6 billion by 2020.
- Segmentation of the microfluidic chips and tests markets, totaling $1.77 billion and $4.5 billion respectively in 2014.
- Descriptions of major product classes and applications such as clinical diagnostics, point-of-care testing, and life sciences research.
- Emerging applications and technologies that provide new functions and benefits.
Organoids are small 3D tissues that mimic the function of organs. They were first developed in 2007 and have since been used to model many organs including the brain, pancreas, and heart. While organoids are still in the early stages of research, they show promise for medical and scientific uses. Organoids are made by harvesting stem cells from an organ and culturing them in a gel environment where they self-organize into ball-like structures that resemble miniature organs. Researchers hope organoids can be used for drug testing and personalized medicine without the need for animal testing. As techniques for growing organoids continue to advance, so too will their potential applications.
Artificial Organ Technology and Market Analysis 2017 Report by Yole Developpe...Yole Developpement
How will artificial organs revolutionize organ transplants and overcome shortages in the next 20 years?
FIVE OUT OF THE TEN LEADING CAUSES OF DEATH IN THE WORLD WILL BENEFIT FROM ARTIFICIAL ORGANS
Organ transplantation is often the only treatment for end-state organ failure, such as liver, kidney and heart failure. Tragically, most people on the waiting list die before they ever get an organ. Hence the dream of developing artificial organs made of electronic and mechanical parts has been around for decades. The first total artificial heart transplant was in the 1980s, yet since then few improvements have made these devices more efficient. Newcomers such as Carmat and Bivacor are aiming to change the paradigm from a single mechanical heart towards a smarter solution, with embedded sensors and intelligence.
The next wave of development came from the diabetes epidemic that affects every country, hitting more than 8% of the global population today. The artificial pancreas market will therefore experience a huge 49% compound annual growth rate (CAGR) over the next five years, to reach $1.3B in 2022. The next breakthrough to happen will come in 5-10 years, bringing artificial lungs and kidneys. The first commercially approved devices will be wearable systems such as the Wearable Artificial Kidney Foundation, Inc. (WAKFI) system.
More information on that report at http://www.i-micronews.com/reports.html
Liquid Biopsy: From Isolation to Downstream Applications 2018 Report by Yole ...Yole Developpement
How will liquid biopsy change cancer care?
More information on: https://www.i-micronews.com/category-listing/product/liquid-biopsy-from-isolation-to-downstream-applications-2018.html
What are Organs-on-chips?
The Organs-on-Chips are crystal clear, flexible polymers about the size of a computer memory stick that contain hollow channels fabricated using computer microchip manufacturing techniques.
These channels are lined by living cells and tissues that mimic organ-level physiology.
Organs-On-Chips Market and Technology Landscape 2019 report by Yole Développe...Yole Developpement
This report provides an analysis of the organ-on-chip market and technology from 2019-2024. It includes market forecasts for organ-on-chip device sales and services through 2024. It also examines the organ-on-chip ecosystem and supply chain, as well as technology trends like the types of organ models, devices, materials, and cell sources used. The report aims to help pharmaceutical, biotech, and other companies understand organ-on-chip technologies and how they can be used for drug development, disease modeling, and toxicity testing applications.
The Promise of Next-Generation Animal Management SystemsCognizant
Pharmaceuticals, biotech and device companies are searching for more robust next-gen animal management systems to help them enhance efficiencies, reduce costs and adhere to regulatory principles for humane animal care. This is an overview of existing systems, and the benefits, challenges, trends and technologies driving them.
Point-of-Need Testing: Application of Microfluidic Technologies - 2018 Report...Yole Developpement
Decentralized testing is now widespread, thanks to the endless possibilities enabled by microfluidic technologies.
More information on that report at https://www.i-micronews.com/report/product/point-of-need-testing-application-of-microfluidic-technologies.html
Microfluidics market outlook Lab On Chip Europe Presentation by Benjamin Rous...Yole Developpement
The document discusses the microfluidics market and industry trends. It provides the following key points:
1) The microfluidics market reached $2.2 billion in 2014 and is growing at a 28% CAGR, though the market remains highly fragmented across applications.
2) The microfluidics industry is consolidating as some companies go public, major diagnostic firms make acquisitions, and the supply chain matures.
3) The technology has moved from the "peak of inflated expectations" to the "slope of enlightenment" on the Gartner Hype Cycle as value is recognized and manufacturing improves.
Status of the Microfluidics Industry 2019 report by Yole Développement Yole Developpement
Diversification of microfluidic technologies has led to burgeoning new applications and market growth, driving players’ interest and M&A.
More information on https://www.i-micronews.com/products/status-of-the-microfluidics-industry-2019/
This document summarizes a presentation on organoids in immunological research. It begins with an overview of organoids, describing them as 3D cultures derived from adult stem cells that recapitulate tissue architecture. Section 1 discusses the tissue-like structure of organoids and self-organization principles. Section 2 explains how organoids can be used to study interactions between epithelial cells and immune cells, and how this improves understanding of homeostasis, infection responses, and fetal development. Section 3 discusses applications of organoid technology in personalized medicine and future directions.
The document discusses organoids, which are 3D clusters of cells grown in vitro to mimic organ structures. It describes the 5 basic steps to make an organoid: 1) obtain a tissue sample, 2) dissociate it into single cells, 3) isolate stem cells using a cell sorter, 4) add the stem cells to a gel-like substance called Matrigel, and 5) allow the cells to grow over 1-90 days. Various types of organoids are listed, and potential uses discussed, including testing medical/chemical agents, aiding drug development by reducing animal testing, and regenerative medicine by growing replacement organs.
Multiorgan Microdevices for ADME Evaluatio and Drug Design:-
Multi-organ micro-devices are microfluidic devices that gives the information of human metabolism by connecting the fluidic streams from several on-chip in vitro tissue cultures with each other in a physiologically relevant manner. Multi-organ micro-devices can predict tissue-tissue interactions that occur as a result of metabolite travel from one tissue to other tissues in vitro. These systems are capable of simulating human metabolism, including the conversion of a pro-drug to its effective metabolite as well as its subsequent active metabolite and toxic side effects. Since tissue-tissue interactions in the human body can play a significant role in determining the success of new pharmaceuticals, the development and use of multi-organ micro-devices present an opportunity to improve the drug development process. The devices have the potential to predict potential toxic side effects with higher accuracy before a drug enters the expensive and time consuming phase of clinical trials. Further, when operated with human biopsy samples, the devices could be a way for the development of individualized medicine. Since single organ devices are testing platforms for tissues that can later be combined with other tissues within multi-organ devices, we will also mention single organ devices where appropriate in the discussion those seems large area of interest in current research for individualized medicine and drug resistance study.
This document discusses the role of nanotechnology in pharmacology and drug delivery. It begins with definitions of nanotechnology and nanobiotechnology, then describes applications of nanobiotechnology including nanopharmacology. The key roles of nanotechnology in drug discovery and development, and drug delivery systems are summarized. Specific nanocarrier platforms like liposomes, polymeric nanoparticles, dendrimers, and nanocrystals are discussed in terms of their advantages and challenges for drug delivery. The role of nanodrugs in personalized medicine is also mentioned.
Point-of-Need Testing: Application of Microfluidic Technologies - 2016 Report...Yole Developpement
Decentralized testing for both human and non-human in-vitro diagnostics is increasingly taking advantage of innovative microfluidic technologies
PLENTY OF APPLICATIONS HAVE STARTED TO BENEFIT FROM MICROFLUIDICS FOR DECENTRALIZED TESTING, BUT HAVE NOT REALIZED THEIR FULL POTENTIAL – YET
Point-of-Care (PoC) testing is not a new concept - the first applications arose in the 1990s. Since then, microfluidic technologies have been increasingly used to solve technical problems and bring economic benefits to the healthcare industry. In the past few years, other applications have benefited from recent technological improvements: veterinary testing, environmental testing, agro-food and industrial testing are also part of the scope of the report. Decentralized testing brings significant operational benefits to various players across these applications.
Microfluidics is part of the diagnostics revolution, with an explosion in the number of products on the market. However, with many applications but few solutions existing today, these markets have not yet reached their full potential.
In the report, Yole Développement (Yole)’s analysts explain why the human healthcare market still looks much more attractive to technology developers. However, in the near future the greatest opportunities will be in all the other markets. The report also explores which barriers still need to be taken down for decentralized, or “point-of-need” (PoN), testing to flourish.
Microfluidics-based point-of-need testing will grow from a $2.6B market in 2015 to $10.3B in 2021, which is a 26% compound annual growth rate (CAGR). This value represents more than 500 million tests in 2021, but only 61 million will be outside human diagnostics. In the report, Yole’s analysts detail the evolution of each application in terms of microfluidic technology’s use.
07b. Nanotechnologies for diagnostics and nanomedicine
Lab on a chip: Miniaturization, Soft lithographies, microfluidics (Navier-Stokes equations, laminar flow in microchannels, main microfluidic components), Selected applications to chemical microreactors, separation systems and Lab On a Chip.
Detailed idea on nanotechnology, nanomedicine, types, uses, pharmacotherapy, and future prospects of the nanotechnology. Drug delivery systems, Pharmacokinetics and pharmacodynamics of the nanoparticles are dealt in detail
This document provides an overview of microfluidics presented by Rajan Arora. It defines microfluidics as manipulating small amounts of fluids using channels 10-100 micrometers in size. Typical microfluidic systems are described including a DNA separation system and lab-on-a-chip for diagnosing heart attacks. The origins and history of microfluidics are discussed from Richard Feynman's 1959 talk to developments in the 1990s. Key components, physics principles, and flow mechanisms of microfluidic systems are explained. Various applications are highlighted such as lab-on-a-chip, low-cost paper and plastic-based microfluidics, and emerging uses in textiles, optofluidics and acou
Cell culture is the process of growing cells outside their natural environment. Key events in the history of cell culture include Wilhelm Roux maintaining chicken tissue in saline in 1885, and Harrison establishing the first cell culture in 1907. Traditionally, cells were cultured in 2D monolayers, but 3D cell culture has emerged as a way to better mimic the in vivo microenvironment. 3D cultures can be scaffold-based, using matrices like collagen, or scaffold-free, allowing cell-cell interactions. Technologies like microfluidics and bio-MEMS now aid 3D cell culture research. Careful planning is required to properly design and safely operate a cell culture laboratory.
Lab-on-a-chip technology integrates laboratory functions onto a single chip only millimeters in size through microfluidics and electronic components. Lab-on-chip devices use materials like glass, silicon, polymers and metals in fabrication processes like deposition, etching, and bonding. They contain microchannels for fluid flow and can integrate nanosensors, allowing portable chemical analysis and detection of small molecules. Applications include point-of-care diagnostics, pollution monitoring, and medical testing. Future advancements will rely on microfluidics and molecular biology with nanotechnology playing a key role.
The document discusses how artificial intelligence can help address challenges posed by infectious diseases. It describes how AI uses past disease data to predict outbreaks, and how algorithms created from behavioral and epidemiological data can help target prevention efforts. The document also outlines several successes of AI in predicting disease outbreaks like dengue fever in advance. Overall, the document advocates that AI has great potential to help monitor infectious diseases and facilitate more proactive public health responses if its tools are developed and applied effectively.
National guidelines for stem cell research-2017akshaya tomar
The document provides guidelines for stem cell research in India. It classifies stem cell research into permissible, restrictive, and prohibited areas based on ethical and safety concerns. It outlines responsibilities of researchers and institutions in obtaining approvals and ensuring informed consent, safety, and oversight for stem cell derivation, manipulation, and clinical applications. The aim is to promote rigorous scientific research while preventing premature commercialization of unproven stem cell therapies.
Microfluidic Applications 2015 Report by Yole DeveloppementYole Developpement
This document provides a summary and analysis of the microfluidic applications market from 2013 to 2020. It includes:
- An overview of key market segments and the status of the microfluidic market since 2013.
- Market data and forecasts for the microfluidic devices market, which is projected to reach $6 billion by 2020.
- Segmentation of the microfluidic chips and tests markets, totaling $1.77 billion and $4.5 billion respectively in 2014.
- Descriptions of major product classes and applications such as clinical diagnostics, point-of-care testing, and life sciences research.
- Emerging applications and technologies that provide new functions and benefits.
Organoids are small 3D tissues that mimic the function of organs. They were first developed in 2007 and have since been used to model many organs including the brain, pancreas, and heart. While organoids are still in the early stages of research, they show promise for medical and scientific uses. Organoids are made by harvesting stem cells from an organ and culturing them in a gel environment where they self-organize into ball-like structures that resemble miniature organs. Researchers hope organoids can be used for drug testing and personalized medicine without the need for animal testing. As techniques for growing organoids continue to advance, so too will their potential applications.
Artificial Organ Technology and Market Analysis 2017 Report by Yole Developpe...Yole Developpement
How will artificial organs revolutionize organ transplants and overcome shortages in the next 20 years?
FIVE OUT OF THE TEN LEADING CAUSES OF DEATH IN THE WORLD WILL BENEFIT FROM ARTIFICIAL ORGANS
Organ transplantation is often the only treatment for end-state organ failure, such as liver, kidney and heart failure. Tragically, most people on the waiting list die before they ever get an organ. Hence the dream of developing artificial organs made of electronic and mechanical parts has been around for decades. The first total artificial heart transplant was in the 1980s, yet since then few improvements have made these devices more efficient. Newcomers such as Carmat and Bivacor are aiming to change the paradigm from a single mechanical heart towards a smarter solution, with embedded sensors and intelligence.
The next wave of development came from the diabetes epidemic that affects every country, hitting more than 8% of the global population today. The artificial pancreas market will therefore experience a huge 49% compound annual growth rate (CAGR) over the next five years, to reach $1.3B in 2022. The next breakthrough to happen will come in 5-10 years, bringing artificial lungs and kidneys. The first commercially approved devices will be wearable systems such as the Wearable Artificial Kidney Foundation, Inc. (WAKFI) system.
More information on that report at http://www.i-micronews.com/reports.html
Liquid Biopsy: From Isolation to Downstream Applications 2018 Report by Yole ...Yole Developpement
How will liquid biopsy change cancer care?
More information on: https://www.i-micronews.com/category-listing/product/liquid-biopsy-from-isolation-to-downstream-applications-2018.html
This document discusses innovation and pre-clinical development in Brazil. It outlines characteristics of innovative countries, recent advances in science and technology in Brazil, and the growth of post-graduate programs. It then discusses the importance of pre-clinical studies like toxicology, pharmacokinetics, safety pharmacology, and local tolerance to support clinical trials. Finally, it introduces the Centre of Innovation and Pre-Clinical Studies, which aims to conduct pre-clinical research, support pharmaceutical development, and contribute to generating national competence in drug innovation.
The document discusses Strand Genomics Inc., which offers genomic analysis and clinical interpretation software and services. It focuses on personalized medicine by using its StrandOmics platform to analyze genomic data and determine disease risks for individuals. StrandOmics aims to make genomic testing routine in medical care to help clinicians make more informed decisions. Strand has grown to over 200 scientists and serves over 2,000 labs and 100,000 patients. Its partnership with Health Care Global Enterprises successfully piloted cancer risk assessment and molecular diagnosis for over 50 patients in India.
Organ-on-chip Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opp...IMARC Group
The global organ-on-chip market size reached US$ 61.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 541.8 Million by 2032, exhibiting a growth rate (CAGR) of 26.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/organ-on-chip-market
Nucleic Acid Aptamers for Diagnostics and Therapeutics: Global MarketsReportsnReports
This report analyzes the global market for nucleic acid aptamers used for diagnostics and therapeutics. It provides an overview of aptamer applications, analyzes market trends from 2011-2017, and identifies high-growth segments. The 138-page report was published in October 2012 and costs $4,850 for a single-user license. It examines technology growth opportunities for aptamers and profiles major industry players.
Chinese Microfluidics Industry 2018 Report by Yole DeveloppementYole Developpement
Will the Chinese microfluidics industry change the worldwide microfluidic landscape?
More information on that report at: https://www.i-micronews.com/category-listing/product/chinese-microfluidics-industry-2018.html
Organ Preservation Market Growth, Demand and Challenges of the Key Industry P...IMARC Group
The global organ preservation market size reached US$ 187.9 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 313.4 Million by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.
More Info:- https://www.imarcgroup.com/organ-preservation-market
Carole Jones & Gopalan Narayanan share their insights on commercialization of Advanced Therapy Medicinal Products (ATMPs) at the Market Access for Cell and Gene Therapies Conference on October 19th 2017.
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
The document discusses the process and costs associated with drug development. It notes that the average cost to develop a new drug is $350 million to $5.5 billion and the process takes 6.5-7 years from discovery to approval. Key barriers to drug development include high financial costs, lengthy timelines for clinical trials, and regulatory hurdles. Approaches to reduce costs and timelines include greater use of electronic health records, simplifying clinical trial protocols, and utilizing decentralized clinical trial models.
The document summarizes key happenings and trends from the 2014 AACC annual meeting and clinical lab expo in Chicago. Specifically:
- Point of care and infectious disease testing were highlighted areas with over 20% of exhibitors.
- Emerging "grassroots molecular" point of care systems were showcased, including systems from Cepheid, Quidel, Nanosphere, and others aiming to provide sample to result testing outside central labs.
- Animal diagnostics and emerging metabolomics offerings were other notable areas exhibited by some companies seeking new opportunities beyond traditional human diagnostics.
The Science of Launching and Achieving Growth in Oncologyaccenture
We have conducted research to understand how oncology companies are responding to New science, more treatment choices and changing economics. Visit https://accntu.re/2Jn72wq to learn our key takeaways for launching and achieving growth in oncology.
This document discusses strategies and best practices for adopting medical technology. It emphasizes the importance of health technology assessment (HTA) and knowledge translation (KT) in facilitating evidence-informed decision making. Key challenges include gaps between research evidence and clinical practice. Strategies proposed include creating timely evidence reviews, using frameworks like Know4Go to evaluate technologies based on criteria like effectiveness and costs, and developing institutional capacity for HTA-informed decisions. Local contextualization, collaboration, training, and clinician champions are seen as important for successful technology adoption.
Pich Deck for Pepper Bio, for TechCruch's Pitch Deck Teardown seriesHajeJanKamps
This document discusses the limitations of current approaches to drug discovery and development and introduces Pepper's transomics platform as a solution. Specifically:
- Traditional drug R&D focuses on static, limited, and unlinked data that misses causal relationships and the full complexity of biology.
- Pepper's platform incorporates multi-omics data across genomics, transcriptomics, proteomics, and phosphoproteomics to capture a more functional and global understanding of disease biology.
- This transomics approach exceeds other methods in target identification and aims to address key questions in drug development around identifying the right target and developing the right drug for patients.
Genentech was the first biotech company founded in 1976 with the goal of using recombinant DNA technology to develop new drugs. It successfully transferred genes between species and established a new business model in the pharmaceutical industry. While Genentech initially struggled to profit from its technology, by the late 1980s it began showing promising results by altering its business model to focus on areas like oncology, immunology, and neuroscience. It became the first biotech company to go public and bring a genetically engineered drug to market.
Computing and AI technologies for mobile and consumer applications 2021 - SampleYole Developpement
Penetrating everyday products will see the market for AI technologies for the consumer market reach $5.6B in 2026.
More information : https://www.i-micronews.com/products/computing-and-ai-technologies-for-mobile-and-consumer-applications-2021/
For the first time, the processor monitor is including FPGA, CPU, GPU, and APU including all the IDMs, fabless companies, and foundries in the business.
More information : https://www.i-micronews.com/products/application-processor-quarterly-market-monitor/
For the first time in its history, the automotive industry must face new industrial and technological
challenges while undergoing dramatic changes in its value chain.
More information: https://www.i-micronews.com/products/automotive-semiconductor-trends-2021/
MicroLED Displays - Market, Industry and Technology Trends 2021Yole Developpement
Strong momentum for MicroLED with progress on all fronts. Cost is the biggest challenge, but Apple and Samsung are carving paths toward the consumer.
More information; https://www.i-micronews.com/products/microled-displays-market-industry-and-technology-trends-2021/
System-in-Package Technology and Market Trends 2021 - SampleYole Developpement
Through enabling design and supply chain agility, SiP will reach $19B by 2026, with IDMs, OSATs, and foundries taking advantage of it.
More information : https://www.i-micronews.com/products/system-in-package-technology-and-market-trends-2021/
Industrial, consumer, and automotive applications are driving the adoption of neuromorphic computing and sensing technologies. The first products are now hitting the market.
More information: https://www.i-micronews.com/products/neuromorphic-computing-and-sensing-2021/
Beyond communication, silicon photonics is penetrating consumer and automotive – heading to $1.1B in 2026.
More information: https://www.i-micronews.com/products/silicon-photonics-2021/
Semiconductor technologies will enable increased mobility and communication for the soldier of the future. This market will reach $17.5B in 2030+.
More information: https://www.i-micronews.com/products/future-soldier-technologies-2021/
This report from Yole Développement analyzes the high-end performance packaging market. It defines high-end performance packaging as technologies that provide high IO density (≥16/mm2) and fine IO pitch (≤130μm). The report aims to identify relevant technologies, analyze market drivers and challenges, describe technology trends and roadmaps, examine the supply chain landscape, and provide market forecasts. It evaluates the market by technology, end application, and region. The report also profiles key players' technology roadmaps and analyzes intellectual property in the 3D SoC hybrid bonding space.
5G’s Impact on RF Front-End and Connectivity for Cellphones 2020Yole Developpement
An intensifying US-China competition for RF technology supremacy.
More information on: https://www.i-micronews.com/products/5gs-impact-on-rf-front-end-and-connectivity-for-cellphones-2020/
In the ultrasound module market, CMUT and PMUT are growing two times faster in medical and consumer applications.
More information: https://www.i-micronews.com/products/ultrasound-sensing-technologies-2020/
The entrance of Chinese players and the rise of new technical solutions are poised to trigger profound changes in the memory business.
More information on: https://www.i-micronews.com/products/status-of-the-memory-industry-2020/
GaAs Wafer and Epiwafer Market: RF, Photonics, LED, Display and PV Applicatio...Yole Developpement
The report provides a market analysis of the GaAs wafer and epiwafer markets from 2019 to 2025. It forecasts that the GaAs wafer market will increase from $200 million in 2019 to $348 million in 2025, with the largest application segments being RF, photonics, and LED. The open epiwafer market is also analyzed, with IQE and VPEC together comprising almost 80% of the $262 million total market in 2019. Key drivers of growth are discussed for various applications such as 5G adoption for RF and increasing use of VCSELs for 3D sensing and LiDAR.
Status of the Radar Industry: Players, Applications and Technology Trends 2020Yole Developpement
Worth more than $20B in 2019, the radar industry is experiencing a major transformation prior to entering the commercial era.
Learn more about the report here: https://www.i-micronews.com/products/status-of-the-radar-industry-players-applications-and-technology-trends-2020/
GaN RF Market: Applications, Players, Technology and Substrates 2020Yole Developpement
Driven by military applications and 5G telecom infrastructure, the GaN RF market continues growing.
Learn more about the report here: https://www.i-micronews.com/products/gan-rf-market-applications-players-technology-and-substrates-2020/
Pressure, inertial, MEMS ultrasound, microfluidic chips and other sensors are driving the growth of the life sciences and healthcare market.
More information: https://www.i-micronews.com/products/biomems-market-and-technology-2020/
Market will more than double by 2025 driven by heavy investments in data centers.
More information: https://www.i-micronews.com/products/optical-transceivers-for-datacom-telecom-2020/
COVID-19 is shaking up the diagnostics industry and will have both short- and long-term impact.
More information: https://www.i-micronews.com/products/point-of-need-2020-including-pcr-based-testing/
Pluggable transceivers in high volume production. Co-packaged optics in line of sight.
More information on: https://www.i-micronews.com/products/silicon-photonics-2020/
Skybuffer SAM4U tool for SAP license adoptionTatiana Kojar
Manage and optimize your license adoption and consumption with SAM4U, an SAP free customer software asset management tool.
SAM4U, an SAP complimentary software asset management tool for customers, delivers a detailed and well-structured overview of license inventory and usage with a user-friendly interface. We offer a hosted, cost-effective, and performance-optimized SAM4U setup in the Skybuffer Cloud environment. You retain ownership of the system and data, while we manage the ABAP 7.58 infrastructure, ensuring fixed Total Cost of Ownership (TCO) and exceptional services through the SAP Fiori interface.
Monitoring and Managing Anomaly Detection on OpenShift.pdfTosin Akinosho
Monitoring and Managing Anomaly Detection on OpenShift
Overview
Dive into the world of anomaly detection on edge devices with our comprehensive hands-on tutorial. This SlideShare presentation will guide you through the entire process, from data collection and model training to edge deployment and real-time monitoring. Perfect for those looking to implement robust anomaly detection systems on resource-constrained IoT/edge devices.
Key Topics Covered
1. Introduction to Anomaly Detection
- Understand the fundamentals of anomaly detection and its importance in identifying unusual behavior or failures in systems.
2. Understanding Edge (IoT)
- Learn about edge computing and IoT, and how they enable real-time data processing and decision-making at the source.
3. What is ArgoCD?
- Discover ArgoCD, a declarative, GitOps continuous delivery tool for Kubernetes, and its role in deploying applications on edge devices.
4. Deployment Using ArgoCD for Edge Devices
- Step-by-step guide on deploying anomaly detection models on edge devices using ArgoCD.
5. Introduction to Apache Kafka and S3
- Explore Apache Kafka for real-time data streaming and Amazon S3 for scalable storage solutions.
6. Viewing Kafka Messages in the Data Lake
- Learn how to view and analyze Kafka messages stored in a data lake for better insights.
7. What is Prometheus?
- Get to know Prometheus, an open-source monitoring and alerting toolkit, and its application in monitoring edge devices.
8. Monitoring Application Metrics with Prometheus
- Detailed instructions on setting up Prometheus to monitor the performance and health of your anomaly detection system.
9. What is Camel K?
- Introduction to Camel K, a lightweight integration framework built on Apache Camel, designed for Kubernetes.
10. Configuring Camel K Integrations for Data Pipelines
- Learn how to configure Camel K for seamless data pipeline integrations in your anomaly detection workflow.
11. What is a Jupyter Notebook?
- Overview of Jupyter Notebooks, an open-source web application for creating and sharing documents with live code, equations, visualizations, and narrative text.
12. Jupyter Notebooks with Code Examples
- Hands-on examples and code snippets in Jupyter Notebooks to help you implement and test anomaly detection models.
Connector Corner: Seamlessly power UiPath Apps, GenAI with prebuilt connectorsDianaGray10
Join us to learn how UiPath Apps can directly and easily interact with prebuilt connectors via Integration Service--including Salesforce, ServiceNow, Open GenAI, and more.
The best part is you can achieve this without building a custom workflow! Say goodbye to the hassle of using separate automations to call APIs. By seamlessly integrating within App Studio, you can now easily streamline your workflow, while gaining direct access to our Connector Catalog of popular applications.
We’ll discuss and demo the benefits of UiPath Apps and connectors including:
Creating a compelling user experience for any software, without the limitations of APIs.
Accelerating the app creation process, saving time and effort
Enjoying high-performance CRUD (create, read, update, delete) operations, for
seamless data management.
Speakers:
Russell Alfeche, Technology Leader, RPA at qBotic and UiPath MVP
Charlie Greenberg, host
Essentials of Automations: Exploring Attributes & Automation ParametersSafe Software
Building automations in FME Flow can save time, money, and help businesses scale by eliminating data silos and providing data to stakeholders in real-time. One essential component to orchestrating complex automations is the use of attributes & automation parameters (both formerly known as “keys”). In fact, it’s unlikely you’ll ever build an Automation without using these components, but what exactly are they?
Attributes & automation parameters enable the automation author to pass data values from one automation component to the next. During this webinar, our FME Flow Specialists will cover leveraging the three types of these output attributes & parameters in FME Flow: Event, Custom, and Automation. As a bonus, they’ll also be making use of the Split-Merge Block functionality.
You’ll leave this webinar with a better understanding of how to maximize the potential of automations by making use of attributes & automation parameters, with the ultimate goal of setting your enterprise integration workflows up on autopilot.
zkStudyClub - LatticeFold: A Lattice-based Folding Scheme and its Application...Alex Pruden
Folding is a recent technique for building efficient recursive SNARKs. Several elegant folding protocols have been proposed, such as Nova, Supernova, Hypernova, Protostar, and others. However, all of them rely on an additively homomorphic commitment scheme based on discrete log, and are therefore not post-quantum secure. In this work we present LatticeFold, the first lattice-based folding protocol based on the Module SIS problem. This folding protocol naturally leads to an efficient recursive lattice-based SNARK and an efficient PCD scheme. LatticeFold supports folding low-degree relations, such as R1CS, as well as high-degree relations, such as CCS. The key challenge is to construct a secure folding protocol that works with the Ajtai commitment scheme. The difficulty, is ensuring that extracted witnesses are low norm through many rounds of folding. We present a novel technique using the sumcheck protocol to ensure that extracted witnesses are always low norm no matter how many rounds of folding are used. Our evaluation of the final proof system suggests that it is as performant as Hypernova, while providing post-quantum security.
Paper Link: https://eprint.iacr.org/2024/257
"Frontline Battles with DDoS: Best practices and Lessons Learned", Igor IvaniukFwdays
At this talk we will discuss DDoS protection tools and best practices, discuss network architectures and what AWS has to offer. Also, we will look into one of the largest DDoS attacks on Ukrainian infrastructure that happened in February 2022. We'll see, what techniques helped to keep the web resources available for Ukrainians and how AWS improved DDoS protection for all customers based on Ukraine experience
How to Interpret Trends in the Kalyan Rajdhani Mix Chart.pdfChart Kalyan
A Mix Chart displays historical data of numbers in a graphical or tabular form. The Kalyan Rajdhani Mix Chart specifically shows the results of a sequence of numbers over different periods.
How information systems are built or acquired puts information, which is what they should be about, in a secondary place. Our language adapted accordingly, and we no longer talk about information systems but applications. Applications evolved in a way to break data into diverse fragments, tightly coupled with applications and expensive to integrate. The result is technical debt, which is re-paid by taking even bigger "loans", resulting in an ever-increasing technical debt. Software engineering and procurement practices work in sync with market forces to maintain this trend. This talk demonstrates how natural this situation is. The question is: can something be done to reverse the trend?
Introduction of Cybersecurity with OSS at Code Europe 2024Hiroshi SHIBATA
I develop the Ruby programming language, RubyGems, and Bundler, which are package managers for Ruby. Today, I will introduce how to enhance the security of your application using open-source software (OSS) examples from Ruby and RubyGems.
The first topic is CVE (Common Vulnerabilities and Exposures). I have published CVEs many times. But what exactly is a CVE? I'll provide a basic understanding of CVEs and explain how to detect and handle vulnerabilities in OSS.
Next, let's discuss package managers. Package managers play a critical role in the OSS ecosystem. I'll explain how to manage library dependencies in your application.
I'll share insights into how the Ruby and RubyGems core team works to keep our ecosystem safe. By the end of this talk, you'll have a better understanding of how to safeguard your code.
Driving Business Innovation: Latest Generative AI Advancements & Success StorySafe Software
Are you ready to revolutionize how you handle data? Join us for a webinar where we’ll bring you up to speed with the latest advancements in Generative AI technology and discover how leveraging FME with tools from giants like Google Gemini, Amazon, and Microsoft OpenAI can supercharge your workflow efficiency.
During the hour, we’ll take you through:
Guest Speaker Segment with Hannah Barrington: Dive into the world of dynamic real estate marketing with Hannah, the Marketing Manager at Workspace Group. Hear firsthand how their team generates engaging descriptions for thousands of office units by integrating diverse data sources—from PDF floorplans to web pages—using FME transformers, like OpenAIVisionConnector and AnthropicVisionConnector. This use case will show you how GenAI can streamline content creation for marketing across the board.
Ollama Use Case: Learn how Scenario Specialist Dmitri Bagh has utilized Ollama within FME to input data, create custom models, and enhance security protocols. This segment will include demos to illustrate the full capabilities of FME in AI-driven processes.
Custom AI Models: Discover how to leverage FME to build personalized AI models using your data. Whether it’s populating a model with local data for added security or integrating public AI tools, find out how FME facilitates a versatile and secure approach to AI.
We’ll wrap up with a live Q&A session where you can engage with our experts on your specific use cases, and learn more about optimizing your data workflows with AI.
This webinar is ideal for professionals seeking to harness the power of AI within their data management systems while ensuring high levels of customization and security. Whether you're a novice or an expert, gain actionable insights and strategies to elevate your data processes. Join us to see how FME and AI can revolutionize how you work with data!
For the full video of this presentation, please visit: https://www.edge-ai-vision.com/2024/06/temporal-event-neural-networks-a-more-efficient-alternative-to-the-transformer-a-presentation-from-brainchip/
Chris Jones, Director of Product Management at BrainChip , presents the “Temporal Event Neural Networks: A More Efficient Alternative to the Transformer” tutorial at the May 2024 Embedded Vision Summit.
The expansion of AI services necessitates enhanced computational capabilities on edge devices. Temporal Event Neural Networks (TENNs), developed by BrainChip, represent a novel and highly efficient state-space network. TENNs demonstrate exceptional proficiency in handling multi-dimensional streaming data, facilitating advancements in object detection, action recognition, speech enhancement and language model/sequence generation. Through the utilization of polynomial-based continuous convolutions, TENNs streamline models, expedite training processes and significantly diminish memory requirements, achieving notable reductions of up to 50x in parameters and 5,000x in energy consumption compared to prevailing methodologies like transformers.
Integration with BrainChip’s Akida neuromorphic hardware IP further enhances TENNs’ capabilities, enabling the realization of highly capable, portable and passively cooled edge devices. This presentation delves into the technical innovations underlying TENNs, presents real-world benchmarks, and elucidates how this cutting-edge approach is positioned to revolutionize edge AI across diverse applications.
Taking AI to the Next Level in Manufacturing.pdfssuserfac0301
Read Taking AI to the Next Level in Manufacturing to gain insights on AI adoption in the manufacturing industry, such as:
1. How quickly AI is being implemented in manufacturing.
2. Which barriers stand in the way of AI adoption.
3. How data quality and governance form the backbone of AI.
4. Organizational processes and structures that may inhibit effective AI adoption.
6. Ideas and approaches to help build your organization's AI strategy.
5th LF Energy Power Grid Model Meet-up SlidesDanBrown980551
5th Power Grid Model Meet-up
It is with great pleasure that we extend to you an invitation to the 5th Power Grid Model Meet-up, scheduled for 6th June 2024. This event will adopt a hybrid format, allowing participants to join us either through an online Mircosoft Teams session or in person at TU/e located at Den Dolech 2, Eindhoven, Netherlands. The meet-up will be hosted by Eindhoven University of Technology (TU/e), a research university specializing in engineering science & technology.
Power Grid Model
The global energy transition is placing new and unprecedented demands on Distribution System Operators (DSOs). Alongside upgrades to grid capacity, processes such as digitization, capacity optimization, and congestion management are becoming vital for delivering reliable services.
Power Grid Model is an open source project from Linux Foundation Energy and provides a calculation engine that is increasingly essential for DSOs. It offers a standards-based foundation enabling real-time power systems analysis, simulations of electrical power grids, and sophisticated what-if analysis. In addition, it enables in-depth studies and analysis of the electrical power grid’s behavior and performance. This comprehensive model incorporates essential factors such as power generation capacity, electrical losses, voltage levels, power flows, and system stability.
Power Grid Model is currently being applied in a wide variety of use cases, including grid planning, expansion, reliability, and congestion studies. It can also help in analyzing the impact of renewable energy integration, assessing the effects of disturbances or faults, and developing strategies for grid control and optimization.
What to expect
For the upcoming meetup we are organizing, we have an exciting lineup of activities planned:
-Insightful presentations covering two practical applications of the Power Grid Model.
-An update on the latest advancements in Power Grid -Model technology during the first and second quarters of 2024.
-An interactive brainstorming session to discuss and propose new feature requests.
-An opportunity to connect with fellow Power Grid Model enthusiasts and users.
Freshworks Rethinks NoSQL for Rapid Scaling & Cost-EfficiencyScyllaDB
Freshworks creates AI-boosted business software that helps employees work more efficiently and effectively. Managing data across multiple RDBMS and NoSQL databases was already a challenge at their current scale. To prepare for 10X growth, they knew it was time to rethink their database strategy. Learn how they architected a solution that would simplify scaling while keeping costs under control.
17. ORDER FORM
Organs-on-Chips
SHIPPING CONTACT
First Name:
Email:
Last Name:
Phone:
PAYMENT
BY CREDIT CARD
Visa Mastercard Amex
Name of the Card Holder:
Credit Card Number:
Card Verification
Value (3 digits except AMEX: 4 digits):
Expiration date:
BY BANK TRANSFER
BANK INFO: HSBC, 1 place de la Bourse,
F-69002 Lyon, France,
Bank code: 30056, Branch code: 00170
Account No: 0170 200 1565 87,
SWIFT or BIC code: CCFRFRPP,
IBAN: FR76 3005 6001 7001 7020 0156 587
RETURN ORDER BY
• FAX: +33 (0)472 83 01 83
• MAIL: YOLE DÉVELOPPEMENT, Le Quartz,
75 Cours Emile Zola, 69100 Villeurbanne/Lyon - France
SALES CONTACTS
• North America - Steve Laferriere: +13106 008 267
laferriere@yole.fr
• Europe RoW - Lizzie Levenez: + 49 15 123 544 182
levenez@yole.fr
• Japan Rest of Asia - Takashi Onozawa: +81 3 6869 6970
onozawa@yole.fr
• Greater China - Mavis Wang: +886 979 336 809
wang@yole.fr
• Specific inquiries: +33 472 830 180 – info@yole.fr
(1)
Our Terms and Conditions of Sale are available at
www.yole.fr/Terms_and_Conditions_of_Sale.aspx
The present document is valid 24 months after its publishing date:
April 5, 2017
/
ABOUT YOLE DEVELOPPEMENT
BILL TO
Name (Mr/Ms/Dr/Pr):
Job Title:
Company:
Address:
City:
State:
Postcode/Zip:
Country*:
*VAT ID Number for EU members:
Tel:
Email:
Date:
PRODUCT ORDER - Ref YDMT17013
Please enter my order for above named report:
One user license*: Euro 5,490
Multi user license: Euro 6,490
- The report will be ready for delivery from April 10, 2017
- For price in dollars, please use the day’s exchange rate. All reports are
delivered electronically at payment reception. For French customers,
add 20% for VAT
I hereby accept Yole Développement’s Terms and Conditions of Sale(1)
Signature:
*One user license means only one person at the company can use the report.
Founded in 1998, Yole Développement has grown to become a group of companies providing marketing, technology and strategy consulting, media and corporate
finance services. With a strong focus on emerging applications using silicon and/or micro manufacturing, the Yole Développement group has expanded to include
more than 50 collaborators worldwide covering MEMS, Compound Semiconductors, LED, Displays, Image Sensors, Optoelectronics, Microfluidics Medical,
Advanced Packaging, Manufacturing, Nanomaterials, Power Electronics and Batteries Energy Management.
The “More than Moore” company Yole and its partners System Plus Consulting, Blumorpho, KnowMade and PISEO support industrial companies, investors and
RD organizations worldwide to help them understand markets and follow technology trends to develop their business.
MEDIA EVENTS
• i-Micronews.com, online disruptive technologies website
• @Micronews, weekly e-newsletter
• Communication webcasts services
• Events: Yole Seminars, Market Briefings…
More information on www.i-micronews.com
CONTACTS
For more information about :
• Consulting Services: Jean-Christophe Eloy (eloy@yole.fr)
• Financial Services: Jean-Christophe Eloy (eloy@yole.fr)
• Report Business: Fayçal Khamassi (khamassi@yole.fr)
• Press relations: Sandrine Leroy (leroy@yole.fr)
CONSULTING
• Market data research, marketing analysis
• Technology analysis
• Reverse engineering costing services
• Strategy consulting
• Patent analysis
More information on www.yole.fr
REPORTS
• Collection of technology market reports
• Manufacturing cost simulation tools
• Component reverse engineering costing
analysis
• Patent investigation
More information on www.i-micronews.com/reports
FINANCIAL SERVICES
• Mergers Acquisitions
• Due diligence
• Fundraising
More information on Jean-Christophe Eloy
(eloy@yole.fr)
18. Definitions: “Acceptance”: Action by which the Buyer accepts
the terms and conditions of sale in their entirety. It is done by
signing the purchase order which mentions “I hereby accept
Yole’s Terms and Conditions of Sale”.
“Buyer”: Any business user (i.e. any person acting in the course
of its business activities, for its business needs) entering into the
following general conditions to the exclusion of consumers acting
in their personal interests.
“Contracting Parties” or “Parties”: The Seller on the
one hand and the Buyer on the other hand.
“Intellectual Property Rights” (“IPR”) means any
rights held by the Seller in its Products, including any patents,
trademarks, registered models, designs, copyrights, inventions,
commercial secrets and know-how, technical information,
company or trading names and any other intellectual property
rights or similar in any part of the world, notwithstanding the fact
that they have been registered or not and including any pending
registration of one of the above mentioned rights.
“License”: For the reports and databases, 3 different licenses
are proposed. The buyer has to choose one license:
• One user license: one person at the company can use the report.
• Multi-user license: the report can be used by unlimited users
within the company. Subsidiaries and Joint-Ventures are not
included.
• Corporate license: purchased under “Annual Subscription”
program, the report can be used by unlimited users within the
company. Joint-Ventures are not included.
“Products”: Depending on the purchase order, reports or
database on MEMS, CSC, Optics/MOEMS, Nano, bio… to
be bought either on a unit basis or as an annual subscription.
(i.e. subscription for a period of 12 calendar months). The
annual subscription to a package (i.e. a global discount based
on the number of reports that the Buyer orders or accesses
via the service, a global search service on line on I-micronews
and a consulting approach), is defined in the order. Reports are
established in PowerPoint and delivered on a PDF format and the
database may include Excel files.
“Seller”: Based in Lyon (France headquarters), Yole
Développement is a market research and business development
consultancy company, facilitating market access for advanced
technology industrial projects. With more than 20 market
analysts, Yole works worldwide with the key industrial companies,
RD institutes and investors to help them understand the markets
and technology trends.
1. SCOPE
1.1 The Contracting Parties undertake to observe the following
general conditions when agreed by the Buyer and the Seller.
ANY ADDITIONAL, DIFFERENT, OR CONFLICTING
TERMS AND CONDITIONS IN ANY OTHER DOCUMENTS
ISSUED BY THE BUYER AT ANY TIME ARE HEREBY
OBJECTED TO BY THE SELLER, SHALL BE WHOLLY
INAPPLICABLE TO ANY SALE MADE HEREUNDER AND
SHALL NOT BE BINDING IN ANY WAY ON THE SELLER.
1.2 This agreement becomes valid and enforceable between the
Contracting Parties after clear and non-equivocal consent
by any duly authorized person representing the Buyer. For
these purposes, the Buyer accepts these conditions of sales
when signing the purchase order which mentions “I hereby
accept Yole’s Terms and Conditions of Sale”. This results in
acceptance by the Buyer.
1.3 Orders are deemed to be accepted only upon written
acceptance and confirmation by the Seller, within [7 days] from
the date of order, to be sent either by email or to the Buyer’s
address. In the absence of any confirmation in writing, orders
shall be deemed to have been accepted.
2. MAILING OF THE PRODUCTS
2.1 Products are sent by email to the Buyer:
• within [1]
month from the order for Products already
released; or
• within a reasonable time for Products ordered prior to
their effective release. In this case, the Seller shall use its best
endeavours to inform the Buyer of an indicative release date
and the evolution of the work in progress.
2.2 Some weeks prior to the release date the Seller can propose
a pre-release discount to the Buyer
The Seller shall by no means be responsible for any delay in
respect of article 2.2 above, and including incases where a
new event or access to new contradictory information would
require for the analyst extra time to compute or compare
the data in order to enable the Seller to deliver a high quality
Products.
2.3 The mailing of the Product will occur only upon payment
by the Buyer, in accordance with the conditions contained
in article 3.
2.4. The mailing is operated through electronic means either by
email via the sales department or automatically online via an
email/password. If the Product’s electronic delivery format
is defective, the Seller undertakes to replace it at no charge
to the Buyer provided that it is informed of the defective
formatting within 90 days from the date of the original
download or receipt of the Product.
2.5 The person receiving the Products on behalf of the Buyer
shall immediately verify the quality of the Products and their
conformity to the order. Any claim for apparent defects or
for non-conformity shall be sent in writing to the Seller within
8 days of receipt of the Products. For this purpose, the Buyer
agrees to produce sufficient evidence of such defects. .
2.6 No return of Products shall be accepted without prior
information to the Seller, even in case of delayed delivery.
Any Product returned to the Seller without providing prior
information to the Seller as required under article 2.5 shall
remain at the Buyer’s risk.
3. PRICE, INVOICING AND PAYMENT
3.1 Prices are given in the orders corresponding to each Product
sold on a unit basis or corresponding to annual subscriptions.
They are expressed to be inclusive of all taxes. The prices
may be reevaluated from time to time. The effective price is
deemed to be the one applicable at the time of the order.
3.2 Yole may offer a pre release discount for the companies willing
to acquire in the future the specific report and agreeing on the
fact that the report may be release later than the anticipated
release date. In exchange to this uncertainty, the company will
get a discount that can vary from 15% to 10%.
3.3 Payments due by the Buyer shall be sent by cheque payable to
Yole Développement, credit card or by electronic transfer to
the following account:
HSBC, 1 place de la Bourse 69002 Lyon France
Bank code: 30056
Branch code: 00170
Account n°: 0170 200 1565 87
BIC or SWIFT code: CCFRFRPP
IBAN: FR76 3005 6001 7001 7020 0156 587
To ensure the payments, the Seller reserves the right to request
down payments from the Buyer. In this case, the need of down
payments will be mentioned on the order.
3.4 Payment is due by the Buyer to the Seller within 30 days
from invoice date, except in the case of a particular written
agreement. If the Buyer fails to pay within this time and fails
to contact the Seller, the latter shall be entitled to invoice
interest in arrears based on the annual rate Refi of the «BCE»
+ 7 points, in accordance with article L. 441-6 of the French
Commercial Code. Our publications (report, database, tool...)
are delivered only after reception of the payment.
3.5 In the event of termination of the contract, or of misconduct,
during the contract, the Seller will have the right to invoice
at the stage in progress, and to take legal action for damages.
4. LIABILITIES
4.1 The Buyer or any other individual or legal person acting on
its behalf, being a business user buying the Products for its
business activities, shall be solely responsible for choosing the
Products and for the use and interpretations he makes of the
documents it purchases, of the results he obtains, and of the
advice and acts it deduces thereof.
4.2 The Seller shall only be liable for (i) direct and (ii) foreseeable
pecuniary loss, caused by the Products or arising from a
material breach of this agreement
4.3 In no event shall the Seller be liable for:
a) damages of any kind, including without limitation, incidental
or consequential damages (including, but not limited to,
damages for loss of profits, business interruption and loss of
programs or information) arising out of the use of or inability
to use the Seller’s website or the Products, or any information
provided on the website, or in the Products;
b) any claim attributable to errors, omissions or other
inaccuracies in the Product or interpretations thereof.
4.4 All the information contained in the Products has been
obtained from sources believed to be reliable. The Seller
does not warrant the accuracy, completeness adequacy or
reliability of such information, which cannot be guaranteed to
be free from errors.
4.5 All the Products that the Seller sells may, upon prior notice
to the Buyer from time to time be modified by or substituted
with similar Products meeting the needs of the Buyer. This
modification shall not lead to the liability of the Seller,
provided that the Seller ensures the substituted Product is
similar to the Product initially ordered.
4.6 In the case where, after inspection, it is acknowledged that
the Products contain defects, the Seller undertakes to replace
the defective products as far as the supplies allow and without
indemnities or compensation of any kind for labor costs,
delays, loss caused or any other reason. The replacement is
guaranteed for a maximum of two months starting from the
delivery date. Any replacement is excluded for any event as set
out in article 5 below.
4.7 The deadlines that the Seller is asked to state for the mailing
of the Products are given for information only and are not
guaranteed. If such deadlines are not met, it shall not lead to
any damages or cancellation of the orders, except for non
acceptable delays exceeding [4] months from the stated
deadline, without information from the Seller. In such case only,
the Buyer shall be entitled to ask for a reimbursement of its first
down payment to the exclusion of any further damages.
4.8 The Seller does not make any warranties, express or implied,
including, without limitation, those of sale ability and fitness for
a particular purpose, with respect to the Products. Although
the Seller shall take reasonable steps to screen Products for
infection of viruses, worms, Trojan horses or other codes
containing contaminating or destructive properties before
making the Products available, the Seller cannot guarantee
that any Product will be free from infection.
5. FORCE MAJEURE
The Seller shall not be liable for any delay in performance directly
or indirectly caused by or resulting from acts of nature, fire, flood,
accident, riot, war, government intervention, embargoes, strikes,
labor difficulties, equipment failure, late deliveries by suppliers or
other difficulties which are beyond the control, and not the fault
of the Seller.
6. PROTECTION OF THE SELLER’S IPR
6.1 All the IPR attached to the Products are and remain the
property of the Seller and are protected under French and
international copyright law and conventions.
6.2 The Buyer agreed not to disclose, copy, reproduce,
redistribute, resell or publish the Product, or any part of it
to any other party other than employees of its company. The
Buyer shall have the right to use the Products solely for its
own internal information purposes. In particular, the Buyer
shall therefore not use the Product for purposes such as:
• Information storage and retrieval systems;
• Recordings and re-transmittals over any network (including
any local area network);
• Use in any timesharing, service bureau, bulletin board or
similar arrangement or public display;
• Posting any Product to any other online service (including
bulletin boards or the Internet);
• Licensing, leasing, selling, offering for sale or assigning the
Product.
6.3 The Buyer shall be solely responsible towards the Seller of
all infringements of this obligation, whether this infringement
comes from its employees or any person to whom the Buyer
has sent the Products and shall personally take care of any
related proceedings, and the Buyer shall bear related financial
consequences in their entirety.
6.4 The Buyer shall define within its company point of contact for
the needs of the contract. This person will be the recipient
of each new report in PDF format. This person shall also be
responsible for respect of the copyrights and will guaranty that
the Products are not disseminated out of the company.
6.5 In the context of annual subscriptions, the person of contact
shall decide who within the Buyer, shall be entitled to access
on line the reports on I-micronews.com. In this respect, the
Seller will give the Buyer a maximum of 10 password, unless
the multiple sites organization of the Buyer requires more
passwords. The Seller reserves the right to check from time
to time the correct use of this password.
6.6 In the case of a multisite, multi license, only the employee
of the buyer can access the report or the employee of the
companies in which the buyer have 100% shares. As a matter
of fact the investor of a company, the joint venture done with
a third party etc..cannot access the report and should pay a
full license price.
7. TERMINATION
7.1 If the Buyer cancels the order in whole or in part or postpones
the date of mailing, the Buyer shall indemnify the Seller for
the entire costs that have been incurred as at the date of
notification by the Buyer of such delay or cancellation. This
may also apply for any other direct or indirect consequential
loss that may be borne by the Seller, following this decision.
7.2 In the event of breach by one Party under these conditions
or the order, the non-breaching Party may send a notification
to the other by recorded delivery letter upon which, after a
period of thirty (30) days without solving the problem, the
non-breaching Party shall be entitled to terminate all the
pending orders, without being liable for any compensation.
8. MISCELLANEOUS
All the provisions of these Terms and Conditions are for the
benefit of the Seller itself, but also for its licensors, employees
and agents. Each of them is entitled to assert and enforce those
provisions against the Buyer.
Any notices under these Terms and Conditions shall be given in
writing. They shall be effective upon receipt by the other Party.
The Seller may, from time to time, update these Terms and
Conditions and the Buyer, is deemed to have accepted the latest
version of these terms and conditions, provided they have been
communicated to him in due time.
9. GOVERNING LAW AND JURISDICTION
9.1 Any dispute arising out or linked to these Terms and
Conditions or to any contract (orders) entered into in
application of these Terms and Conditions shall be settled
by the French Commercial Courts of Lyon, which shall have
exclusive jurisdiction upon such issues.
9.2 French law shall govern the relation between the Buyer and
the Seller, in accordance with these Terms and Conditions.
TERMS AND CONDITIONS OF SALES